Watch AKTX. Know when insiders buy.
One email the day a filing lands. Free.
AKTX
Akari Therapeutics Plc
11.47
+0.63 +5.81%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1786.6BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$31MNET CASH —52W 3.06 – 44.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.6M | −$4.8M | — | 0.00 | −$3.1M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$15.8M | −$14.5M | — | 0.00 | −$2.5M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.2M | −$5.3M | — | 0.00 | −$3M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$7.4M | −$6.4M | — | 0.00 | −$2.1M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$3.1M | −$1.9M | — | 0.00 | −$3.3M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$3.5M | −$3.7M | — | 0.00 | −$2.1M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$5.3M | −$3.8M | — | 0.00 | −$2.1M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$2.9M | −$2.9M | — | 0.00 | −$1.5M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$7.4M | −$7.6M | — | 0.00 | −$4.9M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$6M | −$5.6M | — | 0.00 | −$4M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.1M | −$4.1M | — | 0.00 | −$4.4M | — | — | Apr 15 |
| Q3 2023 · Sep 30 | — | — | — | −$2.5M | −$2.9M | — | 0.00 | −$2.4M | — | — | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$17.3M | −$17.3M | — | 0.00 | −$10.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$21.6M | −$19.8M | — | 0.00 | −$12.6M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$16.8M | −$10M | — | 0.00 | −$16.4M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$23.1M | −$17.7M | — | 0.00 | −$21.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$17.2M | −$17.4M | — | 0.00 | −$18.8M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$18M | −$17.1M | — | -0.01 | −$17M | — | — | — | — |
Every number comes from Akari Therapeutics Plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.